p. 6987−6994
2090-7125
Vol.73/No.7
p. 6995−7005
2090-7125
Vol.73/No.7
p. 7006−7010
2090-7125
Vol.73/No.7
p. 7011−7017
2090-7125
Vol.73/No.7
p. 7018−7024
2090-7125
Vol.73/No.7
p. 7025−7031
2090-7125
Vol.73/No.7
p. 7032−7036
2090-7125
Vol.73/No.7
p. 7037−7041
2090-7125
Vol.73/No.7
p. 7042−7047
2090-7125
Vol.73/No.7
p. 7048−7054
2090-7125
Vol.73/No.7
p. 7055−7063
2090-7125
Vol.73/No.7
p. 7064−7068
2090-7125
Vol.73/No.7
p. 7069−7076
2090-7125
Vol.73/No.7
p. 7085−7089
2090-7125
Vol.73/No.7
0.05).There was a highly significant decrease in serum hepcidin level in IDA group and highly significant increase in hepcidin levels in IRIDA group compared to control group (P=0.000).In IRIDA patients group only there was highly significant increase in hepcidin level in those with mutation in both SNPs together (rs4820268 and rs855791) than patients with one mutation or with wild type(P=0.000).There was a significant decrease in Hb and iron and highly significant decrease in MCV, MCH and ferritin in IRIDA patients with mutation of both SNPs together (rs 4820268 and rs855791) compared to one mutation or wild type (P=0.015,0.016,0.002 ,0.000, 0.006 respectively).Also, there was highly significant decrease in Hb, MCV, MCH and ferritin in IDA patients with mutation of both SNPs together(rs 4820268 and rs 855791) compared to one mutation or wild type (P= 0.002,0.002 ,0.004, 0.009 respectively). In IDA patients there was a significant positive correlation between hepcidin and ferritin (P =0.034, r = 0.279),while there was a significant negative correlation between hepcidin and MCH in IRIDA group (P =0.032, r = - 0.536).Conclusion: In IRIDA the rs4820268 and rs855791 mutations separately or in combination lack inhibitory effect on hepcidin and consequently iron profile and hemoglobin while in IDA although there was significant increase in frequency of rs855791 mutations, there was no effect on hepcidin which suggests that the rs 4820268 mutation is necessary for affecting hepcidin either alone or in combination with rs 855791 mutation. In IDA, there may be other mechanisms or mutations causing anemia.
]]>
p. 7090−7103
2090-7125
Vol.73/No.7
p. 710−7111
2090-7125
Vol.73/No.7
p. 7112−7118
2090-7125
Vol.73/No.7
p. 7119−7126
2090-7125
Vol.73/No.7
p. 7127−7132
2090-7125
Vol.73/No.7
p. 7133−7140
2090-7125
Vol.73/No.7
0.05).
Conclusion: intra-umbilical oxytocin is a useful alternative in patients where methylergometrine is contraindicated or in cases where intravenous fluids need to be restricted. For optimum effect, rapid injection immediately after clamping of the cord is essential.
]]>
p. 7141−7145
2090-7125
Vol.73/No.7
p. 7146−7152
2090-7125
Vol.73/No.7
p. 7153−7159
2090-7125
Vol.73/No.7
p. 7160−7164
2090-7125
Vol.73/No.7
p. 7168−7176
2090-7125
Vol.73/No.7
p. 7177−7181
2090-7125
Vol.73/No.7
p. 7182−7188
2090-7125
Vol.73/No.7
p. 7189−7195
2090-7125
Vol.73/No.7